EASL recommendations on treatment of hepatitis C: Final update of the series

J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018. Epub 2020 Sep 15.


Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region. These European Association for the Study of the Liver recommendations on treatment of hepatitis C describe the optimal management of patients with recently acquired and chronic HCV infections in 2020 and onwards.

Publication types

  • Practice Guideline

MeSH terms

  • Antiviral Agents / pharmacology*
  • Disease Progression
  • Europe / epidemiology
  • Global Health
  • Hepacivirus* / drug effects
  • Hepacivirus* / isolation & purification
  • Hepatitis C* / complications
  • Hepatitis C* / diagnosis
  • Hepatitis C* / drug therapy
  • Hepatitis C* / physiopathology
  • Humans
  • Liver Cirrhosis* / diagnosis
  • Liver Cirrhosis* / etiology
  • Liver Cirrhosis* / prevention & control
  • Liver Cirrhosis* / surgery
  • Liver Transplantation* / adverse effects
  • Liver Transplantation* / methods
  • Monitoring, Physiologic / methods
  • Patient Acuity
  • Patient Care Management* / methods
  • Patient Care Management* / organization & administration
  • Patient Care Management* / standards
  • Patient Care Planning
  • Severity of Illness Index


  • Antiviral Agents